Aurobindo Pharma Limited (AUROPHARMA)
Change in Director(s)
Re-appointment of Mr. Mangalam Ramasubramanian Kumar as Non-executive and Independent Director for a second five-year term starting April 1, 2027, subject to member approval by postal ballot. His first term ends March 31, 2027. He is not related to any current directors or KMP. Mr. Kumar has extensive experience including former Chairman of LIC of India and Non-executive Chairman of Bank of India.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 AUROPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add AUROPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Aurobindo Pharma Limited
Important.
The summary above is generated automatically from Aurobindo Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.